Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

Share Price is delayed by 15 minutes
Get Live Data
36.60    0.10 (0.27%)
Bid:
36.50
Ask:
36.70
Spread: 0.20 (0.548%)
Market Cap: £26.87m
CAR Live PriceLast checked at - London Stock Exchange

Intraday Carclo Share Chart

Interim Management Statement

22 Jan 2014 07:00

RNS Number : 2240Y
Carclo plc
22 January 2014
Β 

22 January 2014

Β 

Carclo plc

("Carclo" or "the group")

Β 

Interim Management Statement

Β 

Β 

The board announces that the group's operating businesses, as expected, are enjoying stronger trading in the second half of the financial year but that lower than previously expected sales at Conductive Inkjet Technology ("CIT") will reduce the forecast profitability of CIT and hence of the group in the second half.

Β 

At CIT, sales of coated film in the second half are set to be ahead of the first half sales number, but below the board's previously disclosed estimated range. This is due to a slower than anticipated ramp up in production on the programs which are using XSenseβ„’ touch sensors. CIT's partner, Atmel Corporation ("Atmel"), recently announced its first production rollout for the HP Omni 10β„’ from its Colorado manufacturing site and Atmel continues to supply XSenseβ„’ for this program. Further programs are expected to progressively come on stream through the first half of 2014, benefitting from the superior capabilities of XSenseβ„’ (including narrow bezel capability) versus competitive offerings.

Β 

The market for XSenseβ„’ and other metal mesh solutions is growing rapidly as adoption begins to gain traction at the expense of ITO touch sensor solutions in this $5 billion market. At the same time we have seen competition in the market increase for all touch solutions, which is causing pricing pressure; while we expect developments in the touch sensor market to become clearer during 2014, this is likely to reduce coated film revenues and margins versus our previous estimates. The product capabilities of XSenseβ„’ are strong and we remain confident that it can gain a significant market share in this rapidly growing market.

Β 

The group's Technical Plastics, LED Technologies and Precision Engineering businesses are all performing in line with the board's expectations.

Β 

Technical Plastics has been awarded several new programs during the year and further significant program awards are anticipated within the next few months as this business enters a growth phase.

Β 

Within the LED Technologies Division we have secured new supercar lighting programs and anticipate further awards early in the next financial year which will drive significant growth in this specialist design and manufacturing business. Sales within the division's LED Optics are also growing well.

Β 

Precision Engineering continues to perform well and has maintained its prior year performance.

Β 

Progress at Carclo Diagnostic Solutions is as anticipated and we are on track to deliver working product prior to our year end for the previously disclosed trial project for an Acute Kidney Injury marker with EKF Diagnostics Systems plc.

Β 

The group's balance sheet is strong and its funding remains secure. The board looks forward to sales and profits progression across the group in the coming financial year.

Β 

Β 

- ENDS -

Β 

Β 

Enquiries:

Carclo plc

01924 268040

Chris Malley, Chief Executive

Robert Brooksbank, Finance Director

Weber Shandwick Financial

020 7067 0700

Nick Oborne / Stephanie Badjonat

Β 

Β 

Notes to editors

Β 

Carclo plc is a technology group. It is a public company whose shares are quoted on the London Stock Exchange.

Β 

Carclo's strategy has been to develop new technologies and products to drive future growth. Its investment in CIT has led to the introduction of a new material for use in Capacitive Touch Screens. Further investment has been made in Carclo Diagnostic Solutions, where a novel Point-of-Care hardware platform has been developed.

Β 

Approximately three fifths of revenues are currently derived from the supply of fine tolerance, injection moulded plastic components, which are used in medical, optical and electronics products. This business, Carclo Technical Plastics, operates internationally in a fast growing and dynamic market underpinned by rapid technological development.

Β 

Approximately two fifths of revenues are derived from the supply of specialised precision LED based systems to the premium automotive industry, as well as key control systems for the aerospace industry.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSPGUPCGUPCUCP
Date   Source Headline
23rd Apr 201911:20 amRNSHolding(s) in Company
18th Apr 20199:32 amRNSHolding(s) in Company
17th Apr 20197:00 amRNSYear-End Trading Update
26th Mar 201912:07 pmRNSSecond Price Monitoring Extn
26th Mar 201912:02 pmRNSPrice Monitoring Extension
26th Feb 20197:00 amRNSHolding(s) in Company
22nd Feb 201910:52 amRNSHolding(s) in Company
19th Feb 20199:39 amRNSAppointment of Chief Operating Officer
19th Feb 20199:16 amRNSHolding(s) in Company
7th Feb 20193:32 pmRNSHolding(s) in Company
6th Feb 20195:57 pmRNSHolding(s) in Company
6th Feb 20191:57 pmRNSHolding(s) in Company
6th Feb 20191:56 pmRNSHolding(s) in Company
6th Feb 201911:51 amRNSHolding(s) in Company
6th Feb 201911:51 amRNSDirector/PDMR Shareholding
31st Jan 201911:12 amRNSHolding(s) in Company
16th Jan 201912:37 pmRNSHolding(s) in Company
16th Jan 201911:43 amRNSHolding(s) in Company
11th Jan 20197:00 amRNSTrading Statement
21st Nov 20182:49 pmRNSHolding(s) in Company
13th Nov 20187:00 amRNSHalf-year Report
12th Oct 20187:00 amRNSTrading Update
29th Aug 20185:08 pmRNSHolding(s) in Company
13th Aug 201811:39 amRNSDirector/PDMR Shareholding
9th Aug 20188:08 amRNSForm 8.3 - [Carclo plc]
9th Aug 20187:24 amRNSForm 8.5 (EPT/RI) Consort Medical Plc
9th Aug 20187:20 amRNSForm 8.5 (EPT/RI) - Carclo Plc
8th Aug 20188:46 amRNSForm 8.3 - [Carclo plc]
7th Aug 20181:46 pmRNSHolding(s) in Company
7th Aug 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
7th Aug 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
7th Aug 201810:36 amRNSForm 8.3 - [Carclo plc]
7th Aug 20189:43 amRNSStatement re withdrawal of Consort Medical plc
7th Aug 20188:23 amRNSConsort Medical No Intention to Bid for Carclo plc
3rd Aug 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
3rd Aug 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
2nd Aug 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
2nd Aug 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
1st Aug 20182:52 pmRNSDirector/PDMR Shareholding
1st Aug 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
1st Aug 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
1st Aug 20189:47 amRNSForm 8 (DD) - Carclo
1st Aug 20189:41 amRNSForm 8 (DD) - Carclo
1st Aug 20189:38 amRNSPerformance Share Plan
1st Aug 20188:19 amRNSForm 8.3 - [Carclo plc]
31st Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
31st Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
31st Jul 201811:01 amRNSForm 8 (DD) - Carclo
31st Jul 201810:54 amRNSDirector/PDMR Shareholding
31st Jul 20189:27 amRNSForm 8.3 - [Carclo plc]

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.